Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy

Deal Worth About $427.5m Upfront

Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.

Film x-ray knee joint with arthritis
Pacira is acquiring Flexion in a deal worth about $427.5m • Source: Shutterstock

Pacira BioSciences, Inc.’s planned acquisition of Flexion Therapeutics, Inc. and its osteoarthritis of the knee injectable Zilretta will allow the company to expand its offering of non-opioid drugs for treating pain while also enabling it to diversify its product offerings away from its flagship post-operative pain drug, Exparel (bupivacaine liposome injectable suspension).

Pacira and Flexion announced the all-cash deal on 11 October and expect it to close within the current quarter. Pacira...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.